Skip to main content
. Author manuscript; available in PMC: 2016 Jul 18.
Published in final edited form as: Ann Allergy Asthma Immunol. 2015 Jan;114(1):58–62.e2. doi: 10.1016/j.anai.2014.10.012

Figure 1.

Figure 1

Placebo or OMA was administered every 2 or 4 weeks. FEV1 was measured at every study visit; PC20 FEV1 to adenosine-5′-monophosphate challenge was measured before and after each treatment period.